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Abstract
Glucose^galactose malabsorption (GGM) is an autosomal recessive disorder caused by defects in the Na/glucose
cotransporter (SGLT1). Neonates present with severe diarrhea while on any diet containing glucose and/or galactose [1]. This
study focuses on a patient of Swiss and Dominican descent. All 15 exons of SGLT1 were screened using single stranded
conformational polymorphism analyses, and aberrant PCR products were sequenced. Two missense mutations, Gly318Arg
and Ala468Val, were identified. SGLT1 mutants were expressed in Xenopus laevis oocytes for radiotracer uptake,
electrophysiological experiments, and Western blotting. Uptakes of [14C]K-methyl-D-glucoside by the mutants were 5% or
less than that of wild-type. Two-electrode voltage-clamp experiments confirmed the transport defects, as no noticeable sugar-
induced current could be elicited from either mutant [2]. Western blots of cell protein showed levels of each SGLT1 mutant
protein comparable to that of wild-type, and that both were core-glycosylated. Presteady-state current measurements
indicated an absence of SGLT1 in the plasma membrane. We suggest that the compound heterozygote missense mutations
G318R and A468V lead to GGM in this patient by defective trafficking of mutant proteins from the endoplasmic reticulum
to the plasma membrane. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cotransporters are a major class of integral mem-
brane proteins responsible for the absorption of var-
ious solutes across the plasma membrane; they con-
centrate substrate molecules into cells by harnessing
the energy from the electrochemical gradient of Na
or H ions. More speci¢cally, the Na/glucose co-
transporter (SGLT1) couples the transport of Na
and glucose across the brush border of the small
intestine. Glucose^galactose malabsorption (GGM)
is an autosomal recessive disorder caused by defects
of SGLT1 [3]. Congenital defects result in severe di-
arrhea and dehydration in the newborn and, if not
diagnosed and treated, the condition can be fatal. On
the other hand, if appropriate dietary carbohydrate
restriction is applied, the diarrhea stops and the child
develops normally.
To date, we have identi¢ed 20 missense mutations
of the SGLT1 gene leading to reduction or elimina-
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tion of transport activity [4^6]. However, only the
mutations identi¢ed in two patients have been
studied in any signi¢cant detail. Here we report the
identi¢cation of two newly recognized mutations in a
GGM patient. Using established techniques and an
oocyte expression system, we identi¢ed speci¢c mu-
tations of each allele, and examined how these muta-
tions cause the defect in sugar transport. The results
suggest that both mutant SGLT1 proteins fail to
correctly tra⁄c from the endoplasmic reticulum to
the plasma membrane.
2. Materials and methods
2.1. Patient background
The proband, C.S., was the 3520-g product of a
normal full-term pregnancy born to a mother of
Swiss, and a father of Dominican descent. Her diet
consisted of both a dextrin^maltose-based formula
and breast milk. After 48 h of life, her stools became
progressively frequent and watery, and she was hos-
pitalized with life-threatening hypernatriemic dehy-
dration. After discontinuing the enteral diet, her di-
arrhea ceased, and subsequent attempts to introduce
lactose, dextrin^maltose or glucose containing foods
resulted in further bouts of diarrhea. A carbohy-
drate-free formula (Nutricia, The Netherlands) with
added fructose was started, and she has thrived since
without further episodes of diarrhea. At age 2.5 years
she tolerated at least 1.25 g (V100 mg/kg b.wt.) of
glucose per day in the form of starch, fruits, and
vegetables.
At age 5 months, galactose malabsorption was
documented by an oral loading test (1 g galactose/
kg b.wt.) after which blood galactose remained un-
measurable and blood glucose unchanged [7]. At age
7 months, several biopsies of the small intestine were
taken. Control biopsies were taken from the same
region of the duodenum of a celiac disease patient
in remission, as proven by histology. Aliquots were
used for in vitro studies of monosaccharide accumu-
lation. The 1-mM glucose accrual factor (tissue to
medium concentration ratio after 1 h) was 2.8 for
glucose (control 5.3) and 2.7 for galactose (control
7.3). These results con¢rmed the clinical diagnosis
and corresponded to published values [8].
We investigated the distribution of SGLT1 by im-
munocytochemistry staining. Other aliquots of the
biopsies were ¢xed in Carnoy’s solution, rinsed
with phosphate-bu¡ered saline, and stored in 20%
(w/v) bu¡ered sucrose. Using a SGLT1 speci¢c anti-
body we were able to identi¢ed the location of the
transporters in the duodenum [9,10].
2.2. Molecular biology
Genomic DNA was extracted from the whole
blood sample and used to amplify all 15 exons and
527 base pairs of the promoter of SGLT1 by polym-
erase chain reaction (PCR) using intron-based oligo-
nucleotides £anking each exon. The oligonucleotides
and the basic methods used are similar to those
described previously [5]. Each exon was screened
against the wild-type product by single-stranded con-
formational polymorphism (SSCP) analysis. The
heat-denatured and labeled PCR product was elec-
trophoresed on a non-denaturing Mutation Detec-
tion Enhancement gel (FMC Bioproducts, Rockland,
ME) for 16 h at 4 W at room temperature. PCR
products with aberrant migration pattern were again
ampli¢ed by PCR without isotope, gel puri¢ed, and
PCR products sequenced bidirectionally using stand-
ard methods to identify the mutations [4,11].
To study the e¡ect of the mutation, site-directed
mutagenesis was used to synthesize the mutant
SGLT1 clones [12]. The ‘mutagenizing’ oligonucleo-
tides used are listed below with the bold letters in-
dicating the mutated nucleotide: G318R-sense, 5P-
GCA TCC TGT GTA GGT ATC TAA AGC-3P,
G318R-antisense, 5P-GCT ATT GAT ACC TAC
ACA GGA TGC-3P ; A468V-sense, 5P-GGG ACC
ACC CAT TGT GGC TGT CTT CC-3P ; and
A468V-antisense, 5P-GGA AGA CAG CCA CAA
TGG GTG GTC CC-3P. The mutant Bluescript plas-
mids were linearized with XbaI, treated with protein-
ase K, extracted with phenol/cholorform, and pre-
cipitated with 2-propanol. In vitro transcription
was performed by a standard protocol using MEGA-
Script T3 Kit from Ambion (Austin, TX).
2.3. Radiotracer uptake and Western blot analysis
Mature oocytes were harvested from Xenopus lae-
vis and injected with 50 ng of capped cRNA for
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SGLT1 coding for human wild-type and the mutants
G318R and A468V. Oocytes were then incubated at
18‡C in Barth’s medium for 5^14 days. Sugar trans-
port was assayed by a radiotracer method. Groups of
8^12 oocytes were incubated for 1 h at 22‡C in 500 Wl
of Na bu¡er containing 50 WM [14C]methyl-D-glu-
coside (K-MDG) (2 WCi/ml) [13].
Injected oocytes were also solubilized in 100 mM
NaCl, 20 mM Tris HCl (pH 7.5), and 1% Elugent
(Calbiochem, CA), and centrifuged to remove insolu-
ble yolk and lipids. Samples were then mixed with
SDS loading bu¡er (2% sodium dodecyl sulfate, 63
mM Tris HCl, pH 6.8, 10% glycerol, 5% L-mercap-
toethanol, and 0.01% bromophenol blue) and run on
a 9% Tricine/SDS polyacrylamide electrophoresis
mini gel. Separated proteins were electrotransferred
to nitrocellulose membrane. SGLT1 was detected us-
ing an antibody raised to peptide residues 602^613 in
the C-terminal portion of SGLT1 at a dilution of
1:3000 [14].
2.4. Electrophysiology
A two-microelectrode voltage clamp was used to
measure wild-type and mutant Na/glucose cotrans-
porter expression and kinetics in oocytes [15,16].
Currents measured at di¡erent sugar concentrations
were ¢tted to the equation, I = Imax [S]n/((K0:5)n+[S]n),
where Imax is maximum current, n is the Hill coe⁄-
cient, S is the sugar concentration, and K0:5 is the
sugar concentration that produces Imax/2. These sug-
ar-dependent inward Na currents are directly propor-
tional to sugar uptakes [2]. Membrane potential was
stepped to various voltages ranging from 3150 to 50
mV and pre-steady-state currents were obtained by
subtracting the capacitive component and steady-
state currents from the total membrane current using
a standard protocol. Charge movement (Q) was ob-
tained by the integration of the transient current re-
corded in the absence of sugar after each test poten-
tial [15]. Q/V plots were ¢tted to the Boltzman
equation and the total number of transporters in
the plasma membrane was estimated from
N = Qmax/zWe, where z is the valence of SGLT1, e is
the elementary charge of an electron, and N is the
estimated number of transporters in the plasma
membrane [15,16]. Using freeze-fracture electron mi-
crocopy we have previously demonstrated the valid-
ity of this method to determine the number of wild-
type and mutant SGLT1 proteins in the oocyte plas-
ma membrane [6,10,17]. pClamp software (Axon In-
struments, Foster City, CA) was used to control the
pulse protocol.
3. Results
3.1. Mutation analysis
Only exons 5, 7, 10, and 15 had a normal migra-
tion pattern by SSCP analysis, therefore the remain-
ing exons and promoter region were sequenced bidir-
ectionally. Mutations were identi¢ed only in exons 9
and 12. In exon 9, a glycine at residue 318 was
changed to an arginine (G318R) by a single nucleo-
tide substitution of (GGGCAGG) on one allele.
Similarly, in exon 12, a single nucleotide substitution
of (GCGCGTG) at residue 468 resulted in a change
of an alanine to a valine (A468V) as shown in Fig. 1.
This mutation also resulted in the elimination of a
BsrDI site. With restriction enzyme digestion of pa-
rental and patient DNA, we con¢rmed the presence
of the mutation and that the A468V mutation was
inherited from the mother, suggesting that the father
Fig. 1. Analysis by SSCP and PCR sequencing of the 15 exons
of hSGLT1 identi¢ed two novel missense mutations in exons 9
and 12 in the compound heterozygous patient. In exon 9 of
one allele, a single nucleotide substitution of GGGCAGG at
residue 318 mutated a glycine to an arginine, in exon 12 of the
other allele, substitution of GCGCGTG at residue 468 resulted
in a change of an alanine to a valine.
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was the donor of the G318R mutation. Fig. 2 shows
that both mutations identi¢ed reside in transmem-
brane domains of the secondary structure; G318R
and A468V are located in the eighth and eleventh
transmembrane spans, respectively [18]. No other
mutations were found in other exons by additional
sequencing.
3.2. Glucose uptake and Western analysis
To assess if there are any changes in function due
to the mutations identi¢ed, the oocyte expression
system was used to measure the uptake of radiola-
beled sugar as compared to that of the wild-type.
The [14C]K-MDG uptake of G318R SGLT1 was in-
distinguishable from non-injected oocytes, (i.e. 6 1%
of that of the wild-type) while the uptake for the
A468V SGLT1 was 5% that of wild-type (Fig. 3).
Western blot analysis of oocyte protein demon-
strated that SGLT1 protein synthesis was compara-
ble in wild-type, G318R, and A468V SGLT1 express-
ing oocytes. The intensity of the V60-kDa
immunoreactive SGLT1 band was approximately
the same in all oocytes, but in those expressing
wild-type SGLT1, there was a second immunoreac-
tive band with an apparent molecular weight of V70
kDa (Fig. 4). The 60-kDa protein represents the
core-glycosylated SGLT1 and the 70-kDa protein,
the fully glycosylated protein [10]. It should be noted
that glycosylation is not required for the functional
expression of SGLT1 in oocytes, or the activity of
SGLT1 in brush-border membranes [19,20].
3.3. Electrophysiology
The expressed proteins were studied further by us-
ing electrophysiological techniques. Human wild-
type SGLT1 showed phlorizin-sensitive, sodium-de-
Fig. 2. The locations of GGM missense mutations on the sche-
matic secondary structure of hSGLT1. Highlighted circles de-
note the substitution at the speci¢ed amino acid residues.
G318R and A468V are located in the transmembrane mutation
‘hot spots’ between exons 9 and 12. The mutations of the pro-
band are highlighted.
Fig. 3. [14C]K-MDG radiotracer uptake by Xenopus laevis oo-
cytes injected with 50 ng of cRNA coding for wild-type, mutant
G318R, or A468V hSGLT1. Uptake in 50 WM [14C]K-MDG is
represented by the mean of 12 oocytes. Wild-type hSGLT1 sug-
ar uptake was 366 þ 40 pmol/oocyte/h. G318R sugar uptake
was indistinguishable from that of non-injected oocytes
(4.6 þ 0.25 pmol/oocyte/h), while A468V uptake was 5-fold high-
er (20 þ 2.1 pmol/oocyte/h).
Fig. 4. Western blot analysis of oocytes expressing wild-type,
G318R, or A468V hSGLT1. Protein synthesis was not inter-
rupted by the mutation. The lower band at V60 kDa is present
in all samples in equal intensity and represents the core glyco-
sylated protein. The upper band at V70 kDa in wild-type
hSGLT1 corresponds to the complex glycosylated protein.
G318R lacks the upper band completely and A468V has a
band of very low intensity at that location (6 1% in intensity
of wild-type).
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pendent, sugar-induced Na currents with a K-MDG
K0:5 of 0.9^1.1 mM. The maximum sugar current at
3150 mV was 1900 nA, whereas for the mutant
SGLT1s, there was no noticeable sugar-induced cur-
rent for the entire voltage range tested (Fig. 5).
Integration of the transient currents obtained with
each voltage jump provided the charge transfer, Q.
Using SGLT1 charge movement, we calculated the
number of co-transporters in the plasma membrane.
When the wild-type Q/V curve was ¢tted to the
Boltzman equation with a Qmax of 37 nC, the total
number of co-transporters was determined to be
1.2U1011 transporters. In the case of the mutants,
there was no signi¢cant level of charge movements
(Fig. 6), and this suggests that the mutant cotrans-
porters were not inserted into the oocyte plasma
membrane (i.e. less than 10% of the wild-type co-
transporters). To determine if this was also the case
in the patient’s enterocytes we carried out SGLT1
immunocytochemistry on intestinal biopsies obtained
from the GGM patient and controls. There was a
marked reduction in SGLT1 immunoreactivity in
the patient’s enterocytes, and unlike the normal tis-
sue where immunoreactivity was restricted to the
brush border, intracellular staining was observed be-
tween the nuclei and the brush-border membrane (B.
Hirayama and M. Lostao, personal communication)
[10].
4. Discussion
A major research focus of this laboratory has been
the mechanism of Na and glucose transport across
plasma membranes by SGLT1. One approach is to
identify naturally occurring mutations in the SGLT1
gene in GGM patients. We previously identi¢ed 20
Fig. 5. Steady-state currents produced by wild-type and mutant
hSGLT1. The sugar-induced current produced by wild-type at
3150 mV was 1900 nA, whereas no noticeable currents were in-
duced by G318R or A468V. Injected oocytes expressing wild-
type, G318R, or A468V were incubated in 100 mM NaCl bu¡er
and the di¡erence in steady-state currents between the presence
and absence of 10 mM K-MDG were plotted at each test mem-
brane potential.
Fig. 6. Charge movement in injected oocytes expressing wild-type and mutant hSGLT1. Wild-type shows a Qmax of 37 nC which cor-
respond to 1.2U1011 transporters in the plasma membrane per cell. G318R shows charge movement indistinguishable from non-in-
jected cells while A468V shows a Qmax twice that of background.
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missense mutations in GGM patients that account
for severely impaired Na/glucose transport [4^6].
The most frequent e¡ect of these mutations was to
reduce the number of SGLT1 transporters in the
plasma membrane. In this study, we report on the
identi¢cation of two additional missense mutations,
G318R and A468V, that impair sugar transport by
reducing the number of cotransporters tra⁄cked to
the plasma membrane. G318 and A468 are well con-
served within the large SGLT1 gene family (see [21]).
Both mutations resulted in at least a 95% reduction
of sugar transport as evident from the [14C]K-MDG
uptakes and sugar dependent sodium currents in oo-
cytes (Figs. 3 and 5). Moreover, the SGLT1 charge
measurements (Qmax) indicate that the number of
SGLT1 proteins in the plasma membrane was sub-
stantially smaller in oocytes injected with mutant
cRNAs, less than 10% of wild-type. We have previ-
ously established the validity of charge measurements
to estimate the number of wild-type and mutant
SGLT1 transporters in the plasma membrane of oo-
cytes ^ Qmax is directly proportional to the number
of SGLT1 intramembrane particles in the plasma
membrane [6,10,17]. The e¡ective reduction in num-
ber of transporters was not due to a defect in SGLT1
synthesis or stability since Western blots of cell pro-
tein showed comparable levels of SGLT1 in oocytes
injected with the wild-type or mutant SGLT1 cRNAs
(Fig. 4). However, there was little or no complex
glycosylation of the mutant proteins, suggesting
that the mutations caused a defect in translocation
of SGLT1 between the ER and the Golgi apparatus.
These results indicate that with these two new mis-
sense mutations the defect in sugar transport is due
to a problem in SGLT1 tra⁄cking.
Evidence is rapidly accumulating that many dis-
ease-causing mutations are due to improper tra⁄ck-
ing; these diseases include cystic ¢brosis, retinitis pig-
mentosa, and leprechaunism [22]. In the case of
GGM, the studies of 22 missense mutant SGLT1
proteins in oocytes indicate that this disease is pri-
marily due to improper tra⁄cking. These mutations
are distributed throughout the 664 residue protein:
four are in the external hydrophilic loops, three are
in the cytoplasmic hydrophilic loops, and 15 are
within the membrane domain. The majority of the
mutations involve charged or polar residues, e.g.
G318R in transmembrane helix 8 (TMH8), where it
is anticipated that the charged residue will grossly
destabilize the structure. It is noteworthy that three
are mutations from alanine to valine (A304V in the
intracellular loop between TMH7 and TMH8;
A388V TMH9; and A468V TMH11), suggesting
that changes in bulk at critical domains in the pro-
tein are su⁄cient to cause conformational changes
that alter tra⁄cking. Preliminary studies where
A468 was mutated to 468C, support this notion
[23]. The molecular volume of cysteine (108.5 Aî 3) is
intermediate between that for alanine (88.6 Aî 3) and
valine (140 Aî 3). The A468C SGLT1 protein was
functional, the maximum rate of transport was 25%
of that for wild-type and the glucose K0:5 was in the
normal range (0.8 mM). These results suggest that
simply increasing the bulk of residue 468 from ala-
nine to cysteine to valine in TMH11 causes graded
changes in the 3-D conformation of SGLT1 that in
turn produce graded perturbations in tra⁄cking of
the cotransporter to the plasma membrane.
Finally, eight of 29 GGM patients are compound
heterozygotes; they include both nonsense and
splice-site mutations as well as missense mutations
found in the present case. The fact that 30% of the
GGM patients studied are the result of non-consan-
guineous relationships suggests that there is a pool of
people who are carriers for GGM mutations.
Whether or not these heterozygotes have any im-
paired glucose absorption has yet to be determined,
but it is noted that about 10% of the normal popu-
lation, medical students, showed glucose malabsorp-
tion with H2-breath tests [24].
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